Scalper1 News
Swiss drug giant Novartis (NVS) said Monday that its oral multiple-sclerosis drug Gilenya failed a late-stage clinical trial for a particularly virulent form of the disease. The company said Gilenya didn’t do better than a placebo in patients with progressive primary multiple sclerosis (PPMS). Unlike the more common relapsing-remitting form of the disease, PPMS brings neurologic decline from the outset but with fewer visible symptoms, often Scalper1 News
Scalper1 News